Cost Effectiveness of Cetuximab in 1st-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer in Scotland- A Summary of the Submission to the Scottish Medicines Consortium
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2296
https://www.valueinhealthjournal.com/article/S1098-3015(14)04226-0/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1754
First Page :
A638
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04226-0&doi=10.1016/j.jval.2014.08.2296